A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Recruiting now · Phase 2/Phase 3 · Has a placebo group
Conditions studied: Parkinson Disease
In brief
A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease. The study will consist of a 48-week double-blind treatment phase followed by a 48-week open-label phase.
Key facts
- Study ID
- NCT06976268
- Run by
- Biohaven Therapeutics Ltd.
- People needed
- 550
- Starts
- 2025-05-28
- Expected to finish
- 2028-09-01
- Last updated by the study team
- 2026-08-07
Who can join
Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Site-049 — Birmingham, Alabama, United States (enrolling)
- Site-041 — Los Angeles, California, United States (enrolling)
- Site-031 — Farmington, Connecticut, United States (enrolling)
- Site-028 — New Haven, Connecticut, United States (enrolling)
- Site-038 — Atlantis, Florida, United States (enrolling)
- Site-017 — Boca Raton, Florida, United States (enrolling)
- Site-051 — Maitland, Florida, United States (enrolling)
- Site-027 — Chicago, Illinois, United States (enrolling)
- Site-071 — Boston, Massachusetts, United States (enrolling)
- Site-015 — Farmington Hills, Michigan, United States (enrolling)
- Site-044 — Chesterfield, Missouri, United States (enrolling)
- Site-005 — New York, New York, United States (enrolling)
- Site-091 — Portland, Oregon, United States (enrolling)
- Site-043 — Round Rock, Texas, United States (enrolling)
- Site-074 — Newport News, Virginia, United States (enrolling)
- Site-007 — Bellevue, Washington, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.